We spoke to Professor Hugh Calkins (Nicholas J. Fortuin M.D. Professor of Cardiology, Director, Electrophysiology Laboratory and Arrhythmia Service, Johns Hopkins Hospital, Baltimore, MD, USA) at Heart Rhythm 2019 about upcoming developments in atrial fibrillation (AF) ablation and his thoughts on the use or the discontinuation of anticoagulants in patients without recurrence after AF ablation.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Hugh Calkins is a consultant for and has received honoraria from Biosense Webster, Medtronic, Abbott, Boston Scientific and Boehringer Ingelheim.
Questions:
1. What developments should we expect to see in atrial fibrillation (AF) ablation over the next few years? (0:09)
2. What are your thoughts on the use versus the discontinuation of anticoagulants in patients without recurrence of disease after AF ablation? (0:53)
3. What are your key take-home messages from Heart Rhythm 2019? (2:02)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with Arrhythmia Alliance.
